throbber
Page 1
`
` UNITED STATES PATENT AND TRADEMARK OFFICE
`_________________
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
`- - - - - - - - - - - - - - - - - -x
`KVK TECH, INC.,
`
`::
`
`Case
`Petitioner, :IPR2018-00290
`:
`:Patent No.
`:8,846,100
`
`- v -
`
`SHIRE PLC,
`
`Patent Owner. :
`- - - - - - - - - - - - - - - - - -x
`:
`KVK TECH, INC.,
`:Case
`Petitioner, :IPR2018-00293
`:
`:Patent No.
`:9,173,857
`:
`:
`Patent Owner. :
`- - - - - - - - - - - - - - - - - -x
`January 17, 2019
`9:48 a.m.
`875 Third Avenue
`New York, New York
`DEPOSITION UPON ORAL EXAMINATION OF
`JAMES E. POLLI, Ph.D., held at the
`above-mentioned time and place, before Randi
`Friedman, a Registered Professional Reporter,
`within and for the State of New York.
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`KVK-TECH EXHIBIT 1046
`
`::
`
`- v -
`
`SHIRE PLC,
`
`12
`
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`

`

`Page 2
`
` J. Polli, Ph.D.
`APPEARANCES:
` LUCAS & MERCANTI, LLP
` Attorneys for Petitioner
`
` 30 Broad Street
` New York, New York 10004
` BY: STEVEN ROTH, ESQ.
` DAVID J. GALLUZZO, ESQ.
`
` TROUTMAN SANDERS LLP
` Attorneys for Patent Owner
` 875 Third Avenue
` New York, New York 10022
`
` BY: JOSEPH R. ROBINSON, ESQ.
` TANYA LEAVY
` * * *
`
`1
`2
`3
`
`4
`
`5
`6
`
`78
`
`9
`10
`
`11
`
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 3
`
` J. Polli, Ph.D.
` * * *
` JAMES E. POLLI, Ph.D., the witness
` herein, after first having been duly sworn,
` was examined and testified as follows:
` * * *
` EXAMINATION
`BY MR. ROTH:
` Q Hello, Dr. Polli.
` A Yes, good morning.
` Q I'm Steven Roth, good morning, from
`Lucas & Mercanti, and we represent KVK Tech, Inc.
` Can you please state your full name
`and address?
` A My name is James Edward Polli. My
`address is 12115 Frederick Road, Ellicott City,
`Maryland, E-L-L-I-C-O-T-T City, Maryland, 21042.
` Q You are testifying as an expert for
`the patent owner in connection with two inter
`partes reviews on U.S. Patent Nos. 8,846,100 and
`9,173,857; is that right?
` A Yes, I recognize the last three
`numbers of those two patents, that's right.
` Q And we'll refer to them from here on
`as the '100 patent and the '857 patent; is that
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 4
`
` J. Polli, Ph.D.
`okay?
` A Yes.
` Q You also submitted a declaration in
`both inter partes reviews which I'll abbreviate,
`IPRs; is that right?
` A That's correct.
` Q And they are substantially identical?
` A I'd say that's fair, yes.
` Q Do you know what ADHD is?
` A Yeah, I think I do.
` Q What is it?
` A Normally I hear it referred to as
`ADHD, but just sitting here now, attention
`deficit hyper-something disorder. I forget what
`the H may exactly stand for.
` Q I'm not 100 percent sure myself.
`Hopefully we'll see a document later that will
`inform us.
` Are you an expert in ADHD?
` A No, I'm not an expert in ADHD.
` Q Have you published in the area?
` A I don't believe so.
` Q Do you know --
` A I'm not sure.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 5
`
` J. Polli, Ph.D.
` Q Okay. Do you know what Adderall is?
` A Yes, I do.
` Q It delivers an immediate release of
`amphetamine?
` A Yeah, Adderall is a tradename for a
`product that contains, I think, mixed
`amphetamines I think is -- maybe a little
`slightly more correct. But an amphetamine, so to
`speak.
` Q And it delivers it as an immediate
`release?
` A Yeah, I recall Adderall is an
`immediate release product. That's my
`recollection, yes.
` Q And it's effective for the treatment
`of ADHD?
` A I think so. I mean, if you're asking
`me about the indication in Adderall's prescribing
`information, sitting here, I think so. Maybe I
`just haven't reviewed that particular recently,
`but I would think so, yes.
` Q It provides up to about six hours of
`efficacy for the treatment of ADHD; is that
`right?
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 6
`
` J. Polli, Ph.D.
` A I mean, do you happen to have the
`package insert for Adderall?
` Q Actually, I don't.
` A Okay. I'd like to answer the
`question. The thing that's going through my mind
`is I think the duration of treatment might be a
`function of dosing. I wasn't sure in your
`question if you had a particular dosing regiment
`in mind.
` Q I don't.
` Do you know what Adderall XR is?
` A Yes, I do.
` Q And are you aware that it consists of
`two bead types containing amphetamine; an
`immediate release bead type and a delayed release
`bead type; is that right?
` A Yes, I'm aware of that.
` Q And it's also effective in treating
`ADHD; is that right?
` A Yes, I do know that it is indicated to
`treat ADHD.
` Q And are you aware that it provides up
`to about 12 hours of efficacy for the treatment
`of ADHD?
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 7
`
` J. Polli, Ph.D.
` A That's what I recall, yes. I think
`sometimes there's some ranges, but 12 is a number
`that I do remember sitting here now.
` Q Mydayis, are you familiar with
`Mydayis?
` A I think only through these
`proceedings.
` Q Okay. And Mydayis has three bead
`types containing amphetamine, an immediate
`release, a delayed release and a second delayed
`release, with an overcoating of a sustained
`release material; is that right?
` A I'm less familiar, but I do understand
`that from these proceedings, I suppose.
` Q And in your declaration, you've
`referred to the third bead type as a sustained
`release bead type; is that right?
` A Yeah, I'm thinking about the -- for
`example, the '100 patent, I do refer to that as a
`sustained release bead, that's right.
` Q That third bead in Mydayis, the
`so-called sustained release bead, that releases
`amphetamine slower and further along in the
`gastrointestinal tract than the other two beads;
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 8
`
` J. Polli, Ph.D.
`is that your understanding?
` A You're asking me about Mydayis?
` Q That's correct.
` A I don't remember reviewing the package
`insert for Mydayis; certainly not recently. I'm
`just -- I'm just not sure how Mydayis is
`described.
` Q Okay. So let's look at your
`declaration and look at how you described it --
` A Okay.
` Q -- since I don't have the package
`insert. So this has been previously marked as
`Shire Exhibit 2060.
` That is your declaration?
` A That's right.
` Q And you've signed it on Page 106?
` A That's right.
` MR. ROBINSON: You want to give
` him a copy of the errata sheet as well? Or
` we can make copies if you want.
` MR. ROTH: Okay.
` MR. ROBINSON: Also, this is one
` of two declarations; correct?
` MR. ROTH: That's right.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 9
`
` J. Polli, Ph.D.
` MR. ROBINSON: I just want to make
` it clear.
`BY MR. ROTH:
` Q This is the declaration in the 290
`case. And here is the errata sheet that
`Mr. Robinson handed me this morning and it's
`marked Exhibit 2060.
` A Thank you.
` MR. ROBINSON: Do you want a copy
` of that for yourself?
` MR. ROTH: I think I have one. I
` think you gave us two.
` MR. ROBINSON: One for each case.
` MR. ROTH: I see. No, I don't.
` MR. ROBINSON: I think the
` paragraph numbers are the same.
` MR. ROTH: The declarations are
` the same, so --
`BY MR. ROTH:
` Q So turn to Page 97 --
` A Okay.
` Q -- and look at Paragraph 204.
` A All righty.
` Q In the middle of that paragraph, do
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 10
`
` J. Polli, Ph.D.
`you see a sentence beginning with the word
`"However" on the left?
` A Yes, I do.
` Q Go to the next sentence. It states,
`"The SR beads are releasing later and further
`along the GI tract than the IR and DPR beads"; do
`you see that?
` A Yes, I do.
` Q The SR bead is the sustained release
`bead?
` A That's right.
` MR. ROBINSON: Objection,
` foundation.
`BY MR. ROTH:
` Q The GI tract is gastrointestinal
`tract?
` A That's right.
` Q And the IR and DPR beads are the
`immediate release and delayed release beads; is
`that right?
` A That's right.
` Q DPR means delayed pulse release?
` A That's right.
` Q Okay. And then go down to the next
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 11
`
` J. Polli, Ph.D.
`paragraph. The third line a little bit to the
`right beginning with the word "So." It says, "So
`an SR bead releasing slowly and much later in the
`GI tract would not necessarily release
`amphetamine to the same extent as the other
`beads"; do you see that?
` A Yes, I do.
` Q Are these statements correct?
` MR. ROBINSON: You're allowed to
` read as much as the declaration as you wish.
` THE WITNESS: Yeah, so in this
` section -- so the section on Page 97, I'm
` addressing Dr. Jusko's report. That's was
` what was on my mind, talking about Claims 5
` through 12.
` And -- so the first sentence in
` the first two paragraphs that you point me
` to say to Dr. Jusko, "Opine that AUC would
` not change if the total dose remains the
` same, no matter how it is distributed among
` the beads." And then I was trying to
` address my understanding of his report. So
` I was being somewhat favorable in some of
` these statements.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 12
`
` J. Polli, Ph.D.
` So the question that you asked me
` about, the SR beads are releasing later and
` further along the GI tract than the IR beads
` or DPR beads, this is in the framework of
` what I understand Dr. Jusko was saying.
` I think as far as the accuracy of
` that statement, I would say just taking one
` step back, I mean, this is my own report,
` and I stand by that sentence, but it's in
` the context of addressing Jusko.
` I would say one element that's --
` where there's some uncertainty about that
` statement -- my statement there, is that the
` SR bead is designed to release -- I'm
` sorry -- release later and further along the
` GI tract. Now whether that really happens;
` for example, it may not release at all. I
` think I made reference to that at other
` points in my report. But again, so in that
` way, it may not be exactly correct, but in
` this paragraph, again, I'm trying to address
` Dr. Jusko's point of view, which is -- which
` I do understand that he says, well, it would
` release later. And I have commented before
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 13
`
` J. Polli, Ph.D.
` that I don't believe that's the case.
` And the major point I'm trying to
` make here is that on the very next sentence,
` the more of the dose that is in the SR bead,
` the less likely that it will be full release
` and full absorption of the entire three-bead
` combination. So in this entire paragraph,
` this section, I'm really trying to address
` what Dr. Jusko was saying. That was -- so
` you drew my attention I think to that one
` sentence.
` If I remember your question, you
` also drew my attention to another sentence
` or another phrase. Can you just repeat what
` the second phrase was? Maybe I lost my
` place. I think it was in Paragraph 205.
`BY MR. ROTH:
` Q It says, "So an SR bead releasing
`slowly and much later in the GI tract would not
`necessarily release amphetamine to the same
`extent as the other beads."
` A Yeah. So, again, I'm kind of taking a
`favorable view of Dr. Jusko's baseline
`understanding that even though these SR beads
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 14
`
` J. Polli, Ph.D.
`have not been evaluated previously, that if they
`were -- if they were to, in fact, release slowly
`and much later in the GI tract, a person of
`ordinary skill would certainly recognize that
`just because something does release slower and
`later in the GI tract compared to other types of
`beads, that doesn't necessarily mean they would
`be absorbed to the same extent. And it's
`certainly well recognized -- a person of ordinary
`skill would recognize that, you know, the GI
`tract has a limit. There's temporal limits of a
`lot of SR designs fail because they run out of
`time. The colon is not designed to be an
`absorptive organ of materials in general. So
`that's what I was trying to get at there. I
`don't know of any limitation -- I don't know of
`any errors, if that was the question.
` Q Going back to my question, because you
`supplied a lot of information there; I'm not sure
`I followed it all. In your first statement you
`said the SR beads are releasing later and further
`along the GI tract than the IR and DPR beads.
` Are you standing by that statement?
`Is that statement still true?
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 15
`
` J. Polli, Ph.D.
` A I mean, again, in the context of
`addressing Dr. Jusko's point of view, this is --
`so this is something that I read that I saw in
`his arguments, that the SR beads are releasing
`later and further along in the GI tract. Maybe
`he didn't use exactly those words, but I
`certainly see that he said that.
` But my main point is that, okay, even
`given that --
` Q I'm not asking your main point.
`You've done that already. I'm asking
`specifically about that sentence.
` MR. ROBINSON: Objection. Asked
` and answered twice.
`BY MR. ROTH:
` Q Do you have -- sitting here today, are
`you -- do you, yourself, have any opinion as to
`whether the SR beads are expected to release
`later and slower and further along in the GI
`tract than the IR and DPR beads?
` MR. ROBINSON: Objection; asked
` and answered, and foundation.
` THE WITNESS: You said expected to
` release later? Later than the other types
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 16
`
` J. Polli, Ph.D.
` of beads?
`BY MR. ROTH:
` Q Yes.
` A Any of the DPR beads? I'm just trying
`to understand the comparison of the SR beads
`versus DPR beads.
` Q In the context that you used those
`words here, do you have an expectation that the
`SR beads are expected to release later in the
`GI -- later, further down the GI tract and slower
`than the IR and DPR beads?
` MR. ROBINSON: Objection; asked
` and answered, and foundation.
` THE WITNESS: The thing that's
` going through my mind is for -- relative to
` the IR bead, I would say, yes, I think they
` were designed to be certainly slower.
` The thing that's less uncertain in
` my mind about being able to answer your
` question is, I'm just not sure what SR bead
` you're referring to, because there's several
` formulation factors in SR beads. And then
` compare that to which DPR beads there's
` various formulation factors for DPR beads.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 17
`
` J. Polli, Ph.D.
`BY MR. ROTH:
` Q I'm only referring to what you said
`here. Whatever you were referring to here,
`that's how I want you to answer my question.
` MR. ROBINSON: Objection; asked
` and answered, and foundation.
`BY MR. ROTH:
` Q When you made this statement, do you
`agree that there's an -- do you have an
`expectation that the SR beads are releasing
`later, slower and further along the GI tract than
`the IR and DPR beads?
` MR. ROBINSON: Objection; asked
` and answered.
` THE WITNESS: I certainly -- in
` addressing Dr. Jusko's opinion, I think,
` yes, Dr. Jusko had that expectation that, in
` general, no matter how the SR beads were
` fabricated, that they would be releasing
` later and further along the GI tract than
` any DR bead.
`BY MR. ROTH:
` Q I'm not asking about Dr. Jusko's
`opinion. I'm asking about your opinion. You
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 18
`
` J. Polli, Ph.D.
`didn't say in this statement this is Dr. Jusko's
`opinion. The statement is self-contained. It
`says, "The SR beads are releasing later and
`further along the GI tract than the IR and DPR
`beads."
` MR. ROBINSON: Objection; asked
` and answered, first of all. Secondly,
` mischaracterization of the testimony. The
` statement is not self-contained. The
` statement is part of an entire declaration
` in an entire paragraph.
`BY MR. ROTH:
` Q Is it your opinion, Dr. Polli, is it
`your opinion that the SR bead is expected to
`release later, slower and further along the GI
`tract than the IR and DPR beads?
` MR. ROBINSON: Objection; asked
` and answered. Becoming argumentative,
` repetitive. It's time to move on.
` THE WITNESS: I mean, I think it's
` possible that it could be, but I'm just --
` in your question, I'm not quite sure what --
` I think it's possible to have an SR bead
` that is designed to be slower than a DPR
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 19
`
` J. Polli, Ph.D.
` bead, but not necessarily all. That's the
` uncertainty in my mind. I'm kind of
` wondering which formulations you're thinking
` about in asking the question. That's all.
`BY MR. ROTH:
` Q Do you have any understanding of what
`the SR bead is in the '100 patent?
` A Yes, yes, yes, I do.
` Q It's an amphetamine pellet coated with
`enteric coating and further Surelease.
` MR. ROBINSON: Objection,
` mischaracterizes the reference.
` THE WITNESS: I think that's an
` example, yes. I understand that.
`BY MR. ROTH:
` Q And do you have an understanding of
`what the DPR bead is in the '100 patent?
` A Yes, I do.
` Q Again, that's an amphetamine bead
`coated with a eudragit coating?
` MR. ROBINSON: Objection.
` Mischaracterizes the reference.
` THE WITNESS: I recall some
` examples like that; that's right.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 20
`
` J. Polli, Ph.D.
`BY MR. ROTH:
` Q And do you have an understanding of
`what an immediate release bead is in the '100
`patent?
` A Yes, I do.
` Q That's a bead that's designed to
`release very quickly; right?
` MR. ROBINSON: Objection.
` Mischaracterizes the reference.
` THE WITNESS: I think that's
` correct, yes.
`BY MR. ROTH:
` Q So given those definitions of those
`three beads, given your statement in your report
`that we've been discussing, do you have an
`expectation that the SR bead would be expected to
`release later, slower and further down the GI
`tract than the IR and DPR beads?
` A I mean, you know, I am thinking about
`the '100 patent, and the SR bead did have that
`intent to allow for treatment of ADHD for later
`day to prolong the duration of therapy via the SR
`bead. So in that regard, I would say, yes, I
`think there's some SR beads that had that intent.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 21
`
` J. Polli, Ph.D.
` MR. ROTH: I want to mark an
` exhibit. Mark it as Exhibit 100. Polli
` Exhibit 100.
` (Exhibit Polli 100 was marked.)
`BY MR. ROTH:
` Q This is a July 21st, 2006 Clinical
`Pharmacology/Biopharmaceutics Report, and it is
`the clinical pharmacology pharmaceutics review
`from the FDA website on FDA's review on the new
`drug application for Mydayis, which at the time
`was referred to as SPD465.
` Are you aware that Mydayis was earlier
`referred to as SPD465, Dr. Polli?
` A Not particularly, no.
` Q Okay. So I'd like you to assume for
`purposes of my question that Mydayis -- the
`earlier name for Mydayis was SPD465.
` A Okay.
` Q And you can assume that for the rest
`of the day.
` A Okay.
` Q Can you take a look at the Page 1
`right on the first page, second paragraph?
` A I'm sorry. What was that; second
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 22
`
` J. Polli, Ph.D.
`paragraph?
` Q Right. "The rationale"; do you see
`it?
` A Yes.
` Q Can you read it out loud?
` A Sure. "The rationale for the
`development of SPD465 long-acting Adderall XR is
`to enable primary adult and adolescent ADHD
`patients to benefit from ADHD symptom control
`throughout the entire day, and to extend those
`benefits into the early evening hours following a
`single morning dose."
` Q Assuming that was the rationale for
`developing Mydayis, do you think it was
`reasonable for the inventors to add the SR bead
`to the IR and DPR beads to extend control of
`ADHD?
` MR. ROBINSON: Objection,
` foundation. And assumes the inventors had
` this information.
` THE WITNESS: I'm sorry. What was
` the question again?
` MR. ROTH: Can you read it back?
` (Whereupon the reporter read back
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 23
`
` J. Polli, Ph.D.
` the requested portion of the record.)
` MR. ROBINSON: Objection,
` foundation.
` THE WITNESS: What do you mean by
` "reasonable"?
`BY MR. ROTH:
` Q Did it make sense? Did it have a
`scientific underpinning?
` A I cite some citations in my report
`about the recognition that some patients would
`benefit by longer duration of therapy, but it was
`also recognized that Adderall had tolerance, and
`that sustained release, which often involves
`flatter profiles, is -- had not previously worked
`and would not be expected to work for ADHD with
`treatment with amphetamine.
` Another issue is that, you know,
`trying to get drug absorbed from the colon
`through sustained release, that's beyond even
`this Adderall XR was associated with challenges
`that were known to a person of ordinary skill, in
`terms of the need for the drug to dissolve in a
`colonic environment, and then be absorbed from a
`colonic environment.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 24
`
` J. Polli, Ph.D.
` Q Was there any scientific basis at all
`for the inventors to add the sustained release
`bead to the IR and DPR beads so as to extend
`control of ADHD?
` MR. ROBINSON: Objection,
` foundation.
`BY MR. ROTH:
` Q Or was it just a shot in the dark that
`made no sense?
` MR. ROBINSON: Objection.
` Artificially restricts.
` THE WITNESS: You're talking about
` what was going on -- you're asking me what
` was going on in the minds of the inventors?
`BY MR. ROTH:
` Q No, no. I'm not asking you to read
`their minds. I'm asking you whether it made
`sense objectively to you, for the inventors to
`have added the SR bead to the IR and DPR beads
`with the expectation that it may extend control
`of ADHD?
` MR. ROBINSON: Objection,
` foundation.
` THE WITNESS: I don't think I -- I
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 25
`
` J. Polli, Ph.D.
` mean, I -- I don't think a person of
` ordinary skill would think there would be an
` expectation of success of adding an SR bead
` to essentially replace -- I'm reading this
` paragraph that you drew my attention to in
` this, Clinical Pharmacology/Biopharmaceutics
` Review, to replace an immediate release dose
` of Adderall as given eight hours after the
` original -- after Adderall XR was given.
`BY MR. ROTH:
` Q That's not my question. I'm not
`talking about eight hours of anything, so let me
`restate my question.
` Was it reasonable for the inventors to
`add the SR bead to the two beads that were in
`Adderall XL, the IR and the DPR beads, to extend
`treatment of ADHD?
` MR. ROBINSON: Objection; asked
` and answered. Foundation.
` THE WITNESS: For what particular
` purpose? To extend ADHD treatment?
`BY MR. ROTH:
` Q Is there any scientific basis that
`doing that would extend ADHD treatment?
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 26
`
` J. Polli, Ph.D.
` MR. ROBINSON: Objection; asked
` and answered.
`BY MR. ROTH:
` Q I gather you have a bases to think
`that -- why it might not work. You went through
`that.
` But I'm asking you, is there any basis
`to think that it might work, to add the SR bead
`to the IR and DPR beads to extend treatment of
`ADHD?
` MR. ROBINSON: Objection; asked
` and answered several times. He already told
` you he had no basis.
` MR. ROTH: Please don't coach the
` witness, Mr. Robinson.
` MR. ROBINSON: I'm not. You're
` asking him the same question repeatedly.
` You're badgering.
` THE WITNESS: So just for
` clarification, when you mean extend ADHD
` treatment, compared to, say, something like
` Adderall?
`BY MR. ROTH:
` Q Adderall XR, because Adderall XR has
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 27
`
` J. Polli, Ph.D.
`the IR and the DPR beads. We went through that
`upfront. So let me clarify my question again.
`Thank you for that.
` Did it make any sense, any rational
`basis to add the SR bead to the IR and DPR beads
`in Adderall XL to extend treatment of ADHD beyond
`Adderall XR?
` MR. ROBINSON: Objection; asked
` and answered.
` THE WITNESS: Although there was
` clearly challenges that in my opinion would
` not provide a reasonable expectation of
` success, one could look at it and say, well,
` if we add -- if we somehow are able to get
` drug absorbed much later, I suppose it would
` go along that hope of being able to address
` that problem. I don't think a person of
` ordinary skill would think that it would be
` reasonable. I'm trying to answer your
` question, was there any remote chance.
` That's how I interpreted your question.
`BY MR. ROTH:
` Q That's not my question.
` Was there a rational basis? Did it
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 28
`
` J. Polli, Ph.D.
`make any sense? Was there a scientific basis?
` MR. ROBINSON: Objection; asked
` and answered.
` THE WITNESS: So excluding other
` type of basis that would cause one to have
` doubts about its success?
`BY MR. ROTH:
` Q Correct. We're going to discuss those
`doubts, guaranteed.
` A Okay.
` Q I'm only asking you if there was any
`scientific basis for doing it, for adding the
`sustained release bead to the IR and DPR beads to
`extend evidence.
` MR. ROBINSON: Objection; asked
` and answered several times.
` THE WITNESS: I mean, yeah, yeah,
` so if -- I mean excluding --
`BY MR. ROTH:
` Q Excluding the doubts.
` A Even though there's reasons I think a
`person of ordinary skill would not think it would
`work, I think there's at least a line of thinking
`that it's -- that there could be a way of getting
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 29
`
` J. Polli, Ph.D.
`drug absorbed later.
` Q Where is the -- and that could extend
`treatment of ADHD?
` A You mean if it worked?
` Q Yes.
` A Yeah, if one knew it worked, then I
`think it would work.
` Q Well if one -- is there a rational
`basis to think that it would extend delayed
`delivery, lower in the GI tract, and is there a
`rational basis to think that that might work to
`treat ADHD?
` MR. ROBINSON: Objection; asked
` and answered.
`BY MR. ROTH:
` Q Again, putting aside the doubts that
`you referred to.
` A When you mean "might," that means any
`remote chance.
` Q No. That means -- was -- I'm asking
`you, is there a scientific basis to think that it
`might work?
` MR. ROBINSON: Objection; asked
` and answered.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

`

`Page 30
`
` J. Polli, Ph.D.
` THE WITNESS: I think I addressed
` that. I think if one looks at what was
` known, they would say there wasn't a
` reasonable expectation of success. But I
` understand your question is excluding all
` the negatives. I mean, it is true, even
` though there's several negatives, that if
` you are somehow able to get more drug
` absorbed later, it could address that goal
` of extending the duration of therapy
` relative to Adderall XR.
`BY MR. ROTH:
` Q Where in the body is the SR bead
`released?
` MR. ROBINSON: Objection,
` foundation.
` THE WITNESS: Is there a
` particular SR bead that you're thinking
` about?
`BY MR. ROTH:
` Q The SR bead in Mydayis.
` A I recall there is -- you know what?
`I'm thinking about Adderall XR. I don't know
`that I've seen -- sitting here now, I don't
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-267-6868
`
`Veritext Legal Solutions
`www.veritext.com
`
`516-608-2400
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket